SERA PROGNOSTICS INC-A
SERANASDAQTrading Snapshot
- Day Range
- $1.99 – $2.02
- 52-Week Range
- $1.56 – $3.95
- Volume
- $4.69B
- Avg Volume
- $5.95B
- Shares Outstanding
- 38.2M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $81,000
- Last Q Revenue
- $30,000
- P/E Ratio
- -3.0
- P/S Ratio
- 1102.1x
- EPS (TTM)
- $-0.66
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +47.3%
Why Investors Own SERA
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SERA PROGNOSTICS INC-A
SERA
StockOtter · stockotter.spaceAbout SERA PROGNOSTICS INC-A
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doc
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics NASDAQ: SERA reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guid
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.16 per share a year ago.
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doc